Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Built to be bought? What makes companies acquisition-ready
Regulation & Industry
For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.   11 September 2026
Patent lawyers and judges discuss lofty UPC issues in grand London venue
Regulation & Industry
UPC judges and practitioners from firms including Freshfields, Kather Augenstein, EIP, Simmons & Simmons and Brinkhof converged at CIPA’s annual conference to offer candid views on the court’s biggest pressure points, from overloaded German divisions to harmonisation and cross-court influence.   10 September 2026
J&J names two-decade veteran as chief IP counsel
Careers
The senior lawyer previously led Johnson & Johnson’s global pharmaceutical patent team, advising on patent portfolios, R&D, licensing, M&A and litigation.   10 September 2026
Pharma
Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.   10 September 2026
MedTech
The UPC has handed the medical device company a significant win over continuous glucose monitoring tech, granting a broad provisional injunction after finding that SiBio’s rival system was likely to infringe its European patent.   9 September 2026
Careers
With technical specialisms including nucleic acid technologies, biological therapeutics and vaccines, and diagnostics and biological assays, the new hire adds a life sciences patent specialism to the firm’s growing IP practice.   8 September 2026
Pharma
A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.   7 September 2026
Regulation & Industry
Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.   4 September 2026
Regulation & Industry
Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies.   4 September 2026
MedTech
A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.   3 September 2026